HK1217180A1 - 根據一種核苷轉運載體的水平治療癌症的方法 - Google Patents

根據一種核苷轉運載體的水平治療癌症的方法 Download PDF

Info

Publication number
HK1217180A1
HK1217180A1 HK16105218.7A HK16105218A HK1217180A1 HK 1217180 A1 HK1217180 A1 HK 1217180A1 HK 16105218 A HK16105218 A HK 16105218A HK 1217180 A1 HK1217180 A1 HK 1217180A1
Authority
HK
Hong Kong
Prior art keywords
treating cancer
level
nucleoside transporter
cancer based
nucleoside
Prior art date
Application number
HK16105218.7A
Other languages
English (en)
Chinese (zh)
Inventor
Carla Heise
Original Assignee
阿布拉科斯生物科学有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 阿布拉科斯生物科学有限公司 filed Critical 阿布拉科斯生物科学有限公司
Publication of HK1217180A1 publication Critical patent/HK1217180A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
HK16105218.7A 2013-01-11 2014-01-10 根據一種核苷轉運載體的水平治療癌症的方法 HK1217180A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361848780P 2013-01-11 2013-01-11
US61/848,780 2013-01-11
US201361752397P 2013-01-14 2013-01-14
US61/752,397 2013-01-14
US13/794,486 2013-03-11
US13/794,486 US20140199404A1 (en) 2013-01-11 2013-03-11 Method for treating cancer based on level of a nucleoside transporter
PCT/US2014/011006 WO2014110345A1 (en) 2013-01-11 2014-01-10 Method for treating cancer based on level of a nucleoside transporter

Publications (1)

Publication Number Publication Date
HK1217180A1 true HK1217180A1 (zh) 2016-12-30

Family

ID=51165318

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105218.7A HK1217180A1 (zh) 2013-01-11 2014-01-10 根據一種核苷轉運載體的水平治療癌症的方法

Country Status (7)

Country Link
US (1) US20140199404A1 (https=)
EP (1) EP2943191A4 (https=)
JP (1) JP2016513075A (https=)
CA (1) CA2897673A1 (https=)
HK (1) HK1217180A1 (https=)
MX (1) MX2015008888A (https=)
WO (1) WO2014110345A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103405405A (zh) 2002-12-09 2013-11-27 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
SI1853250T1 (sl) 2005-02-18 2012-01-31 Abraxis Bioscience Llc Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
KR101420445B1 (ko) 2005-08-31 2014-07-16 아브락시스 바이오사이언스, 엘엘씨 수 난용성 제약학적 약제 및 항균제를 포함하는 조성물
EP3470071A1 (en) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
JP5579057B2 (ja) * 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
HRP20192259T1 (hr) 2009-04-15 2020-03-06 Abraxis Bioscience, Llc Pripravci nanočestica bez priona i metode njihove proizvodnje
CA3051495A1 (en) 2010-03-26 2011-09-29 Abraxis Bioscience, Llc Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma
NZ717490A (en) 2010-03-29 2017-12-22 Abraxis Bioscience Llc Methods of treating cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
BR112012030909A2 (pt) 2010-06-04 2020-08-18 Abraxis Bioscience, Llc métodos de tratamento de câncer pancreático
JP6038123B2 (ja) 2011-04-28 2016-12-07 アブラクシス バイオサイエンス， エルエルシー ナノ粒子組成物の脈管内送達およびそれらの使用
JP6216721B2 (ja) 2011-12-14 2017-10-18 アブラクシス バイオサイエンス， エルエルシー 粒子を凍結乾燥または凍結するためのポリマー賦形剤の使用
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
EP2968191B1 (en) 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
PL3998069T3 (pl) 2015-06-29 2025-03-31 Abraxis Bioscience, Llc Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych
WO2017095632A1 (en) * 2015-11-30 2017-06-08 Mayo Foundation For Medical Education And Research Heatr1 as a marker for chemoresistance
BR112019006329A2 (pt) * 2016-10-07 2019-06-25 Abraxis Bioscience Llc métodos de tratamento de câncer do trato biliar
US11306111B2 (en) 2017-07-31 2022-04-19 January Therapeutics, Inc. Organophosphate derivatives
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
US11708637B2 (en) 2019-08-13 2023-07-25 The Regents Of The University Of California Methods of supporting a graphene sheet disposed on a frame support
JP7832108B2 (ja) 2019-10-28 2026-03-17 アブラクシス バイオサイエンス， エルエルシー アルブミンおよびラパマイシンの医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200204907B (en) * 2001-06-26 2003-03-03 Univ Nat Taiwan Collapsin Response Mediator Protein-1.
SI1853250T1 (sl) * 2005-02-18 2012-01-31 Abraxis Bioscience Llc Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
KR20130028727A (ko) * 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
US20130005678A1 (en) * 2010-03-30 2013-01-03 Clavis Pharma Asa Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate
WO2011153009A1 (en) * 2010-06-02 2011-12-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
US20130115628A1 (en) * 2011-08-02 2013-05-09 Ventana Medical Systems, Inc. Method for selection of chemotherapeutic agents for adenocarcinoma cancer

Also Published As

Publication number Publication date
CA2897673A1 (en) 2014-07-17
US20140199404A1 (en) 2014-07-17
WO2014110345A1 (en) 2014-07-17
JP2016513075A (ja) 2016-05-12
EP2943191A4 (en) 2016-07-13
EP2943191A1 (en) 2015-11-18
MX2015008888A (es) 2015-11-13

Similar Documents

Publication Publication Date Title
HK1217180A1 (zh) 根據一種核苷轉運載體的水平治療癌症的方法
HK1217292A1 (zh) 基於k- ras的突变状态治疗癌症的方法
HK1220405A1 (zh) 治疗膀胱癌的方法
MX2018007987A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
MX381140B (es) Métodos para tratar tumores de células epitelioides.
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
MX389228B (es) Composiciones para tratar el cabello.
MX2015011752A (es) Metodos para tratar cancer de pulmon.
EP3188741A4 (en) Compositions and methods for the treating an inflammatory disease or disorder
IL257029A (en) Preparations and methods for nanoparticles for lipophilic forms
HK1219231A1 (zh) 治疗儿童实体瘤的方法
HK1220155A1 (zh) 治疗癌症的方法
HK1245158A1 (zh) 阿吡莫德组合物及其使用方法
EP3214142A4 (en) Curable composition for inkjet, and method for manufacturing electronic component
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
HK1255446A1 (zh) 分子质量保证方法在测序中的应用
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
HK1250944A1 (zh) 用於治疗癌症的方法
EP3309798A4 (en) Surface-coated copper filler, method for producing same and conductive composition
HK1255835A1 (zh) 用於治疗乙型肝炎的治疗组合物及方法
WO2016167944A8 (en) Compositions and methods for treating autism
EP3275450A4 (en) Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis
EP3381472A4 (en) MEDICINAL PRODUCTS FOR THE TREATMENT OR PREVENTION OF DISTURBANCES CAUSED BY TGF SIGNALS AND USE THEREOF
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
HK1222336A1 (zh) 包含胆硷及其衍生物的组合物、其用途以及其制备方法